Dimerix Ltd
Dimerix Engages Everest Medicines to Commercialise DMX-200 Kidney Disease Treatment across Asia
Dimerix inks exclusive DMX-200 FSGS deal with Everest in Asia; upfront $14.1m, potential milestones up to ~$466m and 15% royalties.
Dimerix Completes Adult Dosing for ACTION3 DMX-200 Trial
Dimerix completes adult dosing for ACTION3 DMX-200 in FSGS; 333 patients vs 286 target, boosting statistical power and de-risking regulatory submission.
Dimerix Reports Positive Data Supporting Action3 Study of DMX-200 to Treat Kidney Disease
Dimerix (ASX: DXB) has received final data analysis from the international PARASOL collaboration that reinforces support for proteinuria-based endpoints in its pivotal Phase 3 Action3 study on DMX-200 for the treatment of kidney disease. The multi-centre, randomised, double-blind, placebo-controlled study is testing the drug’s efficacy and safety in patients with focal segmental glomerulosclerosis (FSGS) who are […]
Dimerix and Amicus Therapeutics partner to commercialise kidney disease treatment DMX-200 in the US
Drug developer Dimerix (ASX: DXB) and US biopharmaceuticals company Amicus Therapeutics have entered into an exclusive US licence agreement for the commercialisation of Dimerix’s lead candidate DMX-200. The drug is under development in a pivotal Phase 3 study known as ACTION3 for the treatment of rare-but-fatal kidney disease focal segmental glomerulosclerosis (FSGS). Under the terms […]